Project budget3 801 252 €
ERDF amount2 280 751 €
The common challenge concerned by CoBra project is related to the cancer control plan.
The CoBra project is interested on technological innovation for diagnosis and treatment of localised cancers able to enhance the quality of life for patient and reduce the cancer mortality.
The CoBra project aims to improve the quality of both diagnosis and treatment of localized cancers, by developing innovative technology for biopsy and brachytherapy under MRI control.
- Prototype: to develop a new medical robot prototype for diagnosis and treatment of localized cancers by brachytherapy and biopsy under guidance of MRI. The main localizations are focussed on Prostate and other soft tissues.
- This prototype will contribute in enhancing the practice of the Brachytherapy in the 2 Seas region. At the end of the project, the concept should be tested on biological subjects, before a technological transfer in the region of the 2 Seas.
- Training: to initiate a training programme for practitioners and physicists on MRI based robotic brachytherapy and biopsy in the 2 Seas region.
- Study: to elaborate a map for targeted cancers dispersion in the region of 2 Seas. This allows estimating the optimal placement of the designed concept in the region of the 2 Seas according to the patient concentration.
- Network: to develop a network of SMEs and Start-up for technological transfer of the new designed concept.
Cross border approach
The fight against cancer is a plan that concerns cross-border countries. The 2 Seas region has complementary competences able to reach the overall objectives of the project. Without this cross-border cooperation, it is not feasible to realize this technological innovation. U-Lille (Fr) will contribute to the development of the robot in collaboration with a SME Demcon (Nl); UT-Delft (Nl) will develop specific needles under IRM control; U-Port. (UK) will work on the time optimization of the treatment plan and the cancer mapping in south of UK. COL (Fr) and NHS (UK) are referenced hospital in the 2 Seas region for the Brachytherapy practice, while Oncovet (Fr) will be a platform for principle proof of the concept for treatment of animal cancers. SATT-Nord (Fr) is a company specialized in the intellectual property of the technological innovation. Finally Eurasanté (Fr) will work on the cancer mapping in the continent and links to SMEs in the exploitation of the results of the project.
In March 2019, a plan of accomplishment of the tasks was discussed and validated by all the partners then transmitted to the JS. A model of Inputs / Outputs was obtained, showing interactions between the deliverables and outputs of each partner.
The Kick-off of the project has been organized on the 4th of Oct. 2018 in Portsmouth (UK) with 45 participants, followed by a Joint Annual and Steering Meeting of the project.
For WP1, a state of art of the existing MR based technologies has been studied and analyzed for exploitation within the project specifications.
Concerning WP2, the overall requirements and specifications for LDR/HDR Brachytherapy (D2.1.1-D.2.1.2) and biopsy (D2.2.1) have been achieved. The first mapping of targeted patients from UK (D2.3.1) and the continent (D2.3.2) has been realized based on social and economic indicators of each region.
In WP3, a preliminary work of the patented innovations in the field of MR-medical technologies has been launched to evaluate and realize a positioning of the expected innovation from CoBra.
In WP4, new observer partners have been candidate to CoBra project, three industrials NORAS (Ge) and Eckert & Ziegler-Bebig (Ge), Therapanacea (Fr) where they provided equipment for patient support and dose delivery to design the new robotic concept. The third observer is academic; representing the Mechatronics Lab. from MIT (US), expert in designing innovative mechatronic systems.
Starting from Dec. 18, a technical meeting is organized every 2 weeks (Friday afternoon) using video conference for 1 hour between all the partners. The aim of this periodic meeting is to evaluate the progress of each partner.
From financial management, two partners couldn’t claim at least one time this first year, mainly due to delay in finalizing the check by their FLC.
From budget, it is noticed a gap between the estimated budget for this first year and the real claimed budget. This is due mainly to the delay in the investment on PP8 for MRI technology, where the amount of installation of such equipment increases the budgeted amount of investment. Also the investment of the robot guide (PP1) takes also time to define the best solution within CoBra and should be considered in the second year.
From communication in WP5, CoBra partners participated to 5 events according to their expertise for project dissemination. During the first year, a communication tools have been realized such as: personalized Logo, Website, Leaflet and Poster